T1	Participants 177 229	patients with unresectable pancreatic adenocarcinoma
T2	Participants 686 781	Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas
T3	Participants 1063 1088	25 patients were enrolled
